A review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer.
An Abramson Cancer Center expert explains how departments can leverage informatics during the 10th Annual NANETS Symposium.
A locoregional approach to cancer vaccines, when combined with immunmodulatory antibody therapy, could generate a significant anti-tumor response.
As result of the Medicare Outpatient Prospective Payment System rule, 85% of 340B hospitals will see net payment increases in 2018, with rural hospitals reaping the largest benefits, according to an analysis conducted by Avalere Health that was commissioned by Community Oncology Alliance. This analysis compared 2017 Part B payments with 2018 payments and included 3814 hospitals.
James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
An overview of the data and rationale that led to the approval of nivolumab and pembrolizumab for NSCLC, with an emphasis on specific patient populations likely to benefit from this approach and future directions for clinical research in this area.
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Xgeva (denosumab) has received approval from the US Food and Drug Administration (FDA) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy, and the agent was granted Orphan Drug Designation.
As a first step toward developing quantitative models, investigators recently developed a mathematical framework to simulate the systemic dissemination of T cells activated in response to focal therapy.
Since the identification of the role of the JAK kinase family in the late 1980s, awareness of this has grown significantly. These tyrosine<br /> kinases have been proven to transmit a variety of signals into the cells with many biological consequences, adding to the interest in the targetability of the JAK pathway. However, better understanding of the complexities of JAK signaling are being evaluated in clinical trials.
Although chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.
The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.
Patients with PD-L1-positive non-small cell lung cancer that has metastasized to the brain did better with cemiplimab plus chemotherapy than with investigator's choice of chemotherapy.
Combination of interleukin-12 therapy with HAIP chemotherapy showed strong antitumor activity and manageable safety in metastatic CRC with liver metastases.
Jeffrey J. Raizer, MD, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.
Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.
This past year, 2020, will go down as a practice-changing one for the treatment of esophageal cancer, said Yelena Y. Janjigian, MD.